According to a recent LinkedIn post from Koios Care, the company plans to participate in the AD/PD conference in Copenhagen from March 17–21. The post indicates that Koios Care intends to discuss new insights from analysis of the Q-index study, focusing on Parkinson’s disease patient functioning in daily life and treatment effectiveness over time.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests that Koios Care is positioning its technology around the use of commercial wearables to detect motor complications in Parkinson’s disease. These tools are described as enabling continuous, non-invasive monitoring that may offer an alternative to traditional clinical and pharmacokinetic assessments.
According to the post, such capabilities could support personalized medication timing and more objective monitoring of treatment efficacy. In the context of clinical trials, the company highlights the potential for sensitive remote endpoints that capture patient-relevant outcomes.
The post further suggests that this approach could reduce study costs while helping meet regulatory expectations for real-world evidence in neurology trials. For investors, this emphasis on wearable-based, data-rich endpoints may signal a focus on clinical development partnerships and a business model tied to trial enablement and digital biomarker solutions.
If Koios Care can demonstrate reliable, regulator-acceptable endpoints from commercial wearables, it could strengthen its competitive position in the digital health and neurology research markets. This may open revenue opportunities in supporting pharmaceutical Parkinson’s trials, post-marketing studies, and long-term disease management programs that require continuous remote monitoring.